

FIG. 1

Treatment protocol of HEMC-1 cells




FIG. 2




FIG. 3




FIG. 5




FIG. 4




FIG. 6B



FIG. 6D




FIG. 6A



FIG. 6C




FIG. 7

SMS-14 10^{-7} M



FIG. 8

BIM23014C 10^{-6} M



FIG. 9

BIM23745C 10^{-8} M




FIG. 10

BIM23190C 10^{-9} M




FIG. 11

BIM23268C 10^{-7} M




FIG. 12

BIM23206C 10^{-8} M




FIG. 13

BIM23197C 10^{-7} M




FIG. 14

BIM23120C 10^{-9} M



FIG. 15

BIM23926C 10^{-7} M




FIG. 16

SU5416 10^{-6} M




FIG. 17

8/8

Table 1 Proliferation of HEMC-1 human endothelial cells in vitro

Concentration	BIM-23120C	BIM-23197C	BIM-23206C	BIM-23190C
0 M	% of controls 100	% of controls 100	% of controls 100	% of controls 100
10 ⁻⁶ M			122.58 ± 7.3	113.55 ± 6.5
10 ⁻⁷ M	103.97 ± 2.07	87.61 ± 3.6	81.29 ± 3.2	92.26 ± 3.1
10 ⁻⁸ M	74.27 ± 4.5	78.25 ± 2.5	68.38 ± 3.9	60.0 ± 2.2
10 ⁻⁹ M	88.01 ± 3.7	73.39 ± 2.1	77.42 ± 4.0	87.74 ± 2.5
10 ⁻¹⁰ M	102.39 ± 5.2	83.96 ± 3.2		
BIM-23268C	BIM-23745C	BIM-23014C	BIM-23926C	SMS-14
% of controls 100	% of controls 100	% of controls 100	% of controls 100	% of controls 100
118.06 ± 8.2	40.0 ± 2.0	80.0 ± 3.2	56.78 ± 4.9	73.3 ± 4.1
87.74 ± 3.7	46.55 ± 2.3	51.2 ± 4.7	55.33 ± 3.3	71.25 ± 2.1
111.61 ± 2.5	49.7 ± 1.9	65.05 ± 3.1	65.54 ± 3.5	69.7 ± 2.5
94.19 ± 4.2	56.79 ± 2.7	78.0 ± 2.7	79.95 ± 4.6	77.85 ± 3.3
			88.10 ± 5.3	

Treatment was delivered on day 1, 24 hours after plating and repeated 48 hours later; cell count was performed after additional 24 hours. SMS-14 was added on each day. SU5416 was added at 10⁻⁶ M to culture media of separate wells and resulted in 43.85 ± 3.02% survival as compared to untreated controls.

Table II Proliferation of endothelial cells from blood vessels explanted from human placenta

Concentration	BIM-23120C	BIM-23197C	BIM-23206C	BIM-23190C
0 M	% of controls 100	% of controls 100	% of controls 100	% of controls 100
10 ⁻⁶ M	106.6 ± 10.2	98.99 ± 8.7	93.08 ± 7.8	107.98 ± 8.5
10 ⁻⁷ M	94.78 ± 8.4	62.72 ± 7.9	83.77 ± 10.2	102.39 ± 7.3
10 ⁻⁸ M	88.18 ± 11.3	71.54 ± 8.2	72.07 ± 8.5	95.12 ± 10.7
10 ⁻⁹ M	78.76 ± 7.6	114.23 ± 7.6	97.87 ± 10.9	91.75 ± 10.9
10 ⁻¹⁰ M	86.57 ± 9.8	126.65 ± 11.2	105.32 ± 11.3	103.98 ± 12
BIM-23268C	BIM-23745C	BIM-23014C	BIM-23926C	SMS-14
% of controls 100	% of controls 100	% of controls 100	% of controls 100	% of controls 100
98.14 ± 10.7	70.75 ± 7.5	73.66 ± 8.7	38.39 ± 10.6	73.25 ± 7.5
81.12 ± 11.6	62.99 ± 8.2	79.01 ± 8.2	17.18 ± 11.8	44.03 ± 5.2
84.31 ± 12.1	42.84 ± 5.6	80.24 ± 10.1	41.54 ± 7.9	68.72 ± 5.4
86.97 ± 8.4	63.41 ± 6.8	90.53 ± 11.3	55.94 ± 13.6	84.77 ± 7.1
76.33 ± 7.6	82.43 ± 8.5	90.94 ± 12.6	62.32 ± 12	99.18 ± 7.

Treatments were delivered every after day over a 28-day period. SU5416 was added every two days at 10⁻⁶ M culture media of separate explants and resulted in 32.92 ± 9.7% of SI as compared to untreated controls.